These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 11691826)

  • 61. Detailed mapping of methylcytosine positions at the CpG island surrounding the Pa promoter at the bcr-abl locus in CML patients and in two cell lines, K562 and BV173.
    Fajkusová L; Fajkus J; Polácková K; Fulnecek J; Dvoráková D; Krahulcová E
    Blood Cells Mol Dis; 2000 Jun; 26(3):193-204. PubMed ID: 10950939
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Characterization of a monoclonal antibody specific for novel Bcr/Abl out-of-frame fusion proteins.
    Casnici C; Volpe G; Crotta K; Panuzzo C; Lattuada D; Cabras CA; Longhi R; Saglio G; Marelli O
    Hybridoma (Larchmt); 2011 Jun; 30(3):261-9. PubMed ID: 21707361
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Crk-associated substrate lymphocyte type regulates myeloid cell motility and suppresses the progression of leukemia induced by p210Bcr/Abl.
    Seo S; Nakamoto T; Takeshita M; Lu J; Sato T; Suzuki T; Kamikubo Y; Ichikawa M; Noda M; Ogawa S; Honda H; Oda H; Kurokawa M
    Cancer Sci; 2011 Dec; 102(12):2109-17. PubMed ID: 21848808
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Bcr-Abl regulates osteopontin transcription via Ras, PI-3K, aPKC, Raf-1, and MEK.
    Hickey FB; England K; Cotter TG
    J Leukoc Biol; 2005 Jul; 78(1):289-300. PubMed ID: 15857938
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Abl protein kinase abrogates the response of multipotent haemopoietic cells to the growth inhibitor macrophage inflammatory protein-1 alpha.
    Wark G; Heyworth CM; Spooncer E; Czaplewski L; Francis JM; Dexter TM; Whetton AD
    Oncogene; 1998 Mar; 16(10):1319-24. PubMed ID: 9546433
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer.
    Zámečníkova A
    Expert Rev Hematol; 2010 Feb; 3(1):45-56. PubMed ID: 21082933
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Transcription factor BACH2 is transcriptionally regulated by the BCR/ABL oncogene.
    Vieira SA; Deininger MW; Sorour A; Sinclair P; Foroni L; Goldman JM; Melo JV
    Genes Chromosomes Cancer; 2001 Dec; 32(4):353-63. PubMed ID: 11746976
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Molecular pathogenesis of chronic myeloid leukemia].
    Sasaki K; Mitani K
    Nihon Rinsho; 2009 Oct; 67(10):1894-9. PubMed ID: 19860186
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Specific point mutations that activate v-abl are not found in Philadelphia-negative chronic myeloid leukaemia, Philadelphia-negative acute lymphoblastic leukaemia or blast transformation of chronic myeloid leukaemia.
    Melo JV; Goldman JM
    Leukemia; 1992 Aug; 6(8):786-90. PubMed ID: 1353550
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.
    Nemoto A; Saida S; Kato I; Kikuchi J; Furukawa Y; Maeda Y; Akahane K; Honna-Oshiro H; Goi K; Kagami K; Kimura S; Sato Y; Okabe S; Niwa A; Watanabe K; Nakahata T; Heike T; Sugita K; Inukai T
    Mol Cancer Ther; 2016 Jan; 15(1):94-105. PubMed ID: 26637365
    [TBL] [Abstract][Full Text] [Related]  

  • 71. New insights into the pathogenesis of chronic myeloid leukaemia: towards a path to cure.
    Thielen N; Ossenkoppele GJ; Schuurhuis GJ; Janssen JJ
    Neth J Med; 2011 Oct; 69(10):430-40. PubMed ID: 22058262
    [No Abstract]   [Full Text] [Related]  

  • 72. Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.
    MacPartlin M; Smith AM; Druker BJ; Honigberg LA; Deininger MW
    Leukemia; 2008 Jul; 22(7):1354-60. PubMed ID: 18548107
    [TBL] [Abstract][Full Text] [Related]  

  • 73. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity.
    Puccetti E; Güller S; Orleth A; Brüggenolte N; Hoelzer D; Ottmann OG; Ruthardt M
    Cancer Res; 2000 Jul; 60(13):3409-13. PubMed ID: 10910048
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antisense inhibition of P210 bcr-abl in chronic myeloid leukemia.
    Vaerman JL; Lewalle P; Martiat P
    Stem Cells; 1993 Oct; 11 Suppl 3():89-95. PubMed ID: 8298481
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Study on the treatment of the p15 gene combined with Bcr-abl-specific siRNA and STI571 for chronic myeloid leukemia.
    Wang W; Du Y; Li NN; Lv FF; Lin GQ
    Genet Mol Res; 2014 May; 13(2):4089-101. PubMed ID: 24938701
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines.
    Jonuleit T; van der Kuip H; Miething C; Michels H; Hallek M; Duyster J; Aulitzky WE
    Blood; 2000 Sep; 96(5):1933-9. PubMed ID: 10961897
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A novel variant of the bcr-abl fusion product in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Soekarman D; van Denderen J; Hoefsloot L; Moret M; Meeuwsen T; van Baal J; Hagemeijer A; Grosveld G
    Leukemia; 1990 Jun; 4(6):397-403. PubMed ID: 2193202
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth.
    Okabe M; Uehara Y; Miyagishima T; Itaya T; Tanaka M; Kuni-Eda Y; Kurosawa M; Miyazaki T
    Blood; 1992 Sep; 80(5):1330-8. PubMed ID: 1515646
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Recent advances in molecular biology of chronic myeloid leukaemia: is the pathogenetic puzzle approaching solution?
    Goldman JM
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():129-30. PubMed ID: 2496882
    [TBL] [Abstract][Full Text] [Related]  

  • 80. P210 BCR-ABL is complexed to P160 BCR and ph-P53 proteins in K562 cells.
    Campbell ML; Li W; Arlinghaus RB
    Oncogene; 1990 May; 5(5):773-6. PubMed ID: 2140598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.